

## REMARKS

The present application is a continuation of U.S. Serial No. 08/820,694, which was allowed on August 7, 2001. As this continuation application has been filed before the payment of the Issue Fee, it is timely filed.

The specification has been amended to refer to related patent applications, add interleukin-II as an active agent, and to correct a grammatical error. Support for interleukin-II is found at original claims 3 and 4. Claims 1-19 have been canceled without prejudice. Claims 20-45 have been added. Support for new claims 20-45 is found at original claims 1-19 and page 20, lines 7-13, of the specification.

In a June 3, 1999 Office Action issued in the parent application, U.S. Serial No. 08/820,694, the Examiner rejected claim 1 under 35 U.S.C. §112, first paragraph, alleging that the specification "does not reasonably provide enablement for any substituted phenyl or naphthyl, where all the possible substituents are not readily determined". While applicants disagreed with the Examiner's rejection, the claims were limited to unsubstituted phenyl or naphthyl in order to expedite prosecution of the application.


Applicants have filed this application in order to pursue claims directed to carrier compounds containing a substituted phenyl or naphthyl moiety. The phrase "substituted phenyl or naphthyl" is clearly supported in the original specification for U.S. Serial No. 08/820,694 and in this application at page 17, line 6; page 18, lines 16-18; page 24, line 10-12; and claim 1.

It is believed that the claims are free from any ground for rejection over the prior art. Early passage to allowance is respectfully requested.

Dated: November 7, 2001

DARBY & DARBY, P.C.  
805 Third Avenue  
New York, N.Y. 10022  
Phone (212) 527-7700

Respectfully submitted,



Jay P. Lessler

Reg. No. 41,151

Attorney for Applicants

TO: 44-38861-1000

Marked-Up Specification  
New Continuation Application  
(Docket No. 1946/1B861-US2)  
(Accompanying November 7, 2001 Preliminary Amendment)

**IN THE SPECIFICATION:**

Page 1, lines 11-13:

CROSS-REFERENCE TO OTHER RELATED APPLICATIONS

The present application is a continuation of U.S. Application Serial No. 08/820,694,  
filed March 18, 1997, and claims the benefit under 35 U.S.C. §119 of [based upon one] U.S.  
Provisional Patent Application Serial No. 60/017,902, filed March 29, 1996, both of which are  
hereby incorporated by reference and made part of the instant disclosure. [Applicant claims the  
benefit of the filing dates of the aforesaid provisional application under 35 U.S.C. §119.]

Page 20, lines 5-20:

Biologically or chemically active agents include, but are not limited to, pesticides,  
pharmacological agents, and therapeutic agents. For example, biologically or chemically active  
agents suitable for use in the present invention include, but are not limited to, peptides, and  
particularly small peptides; hormones, and particularly hormones which by themselves do not or only  
a fraction of the administered dose passes through the gastro-intestinal mucosa and/or are susceptible  
to chemical cleavage by acids and enzymes in the gastro-intestinal tract; polysaccharides, and  
particularly mixtures of muco-polysaccharides; carbohydrates; lipids; or any combination thereof.  
Further examples include, but are not limited to, human growth hormones; bovine growth hormones;

growth releasing hormones; interferons; interleukin-1; interleukin-II; insulin; heparin, and particularly low molecular weight heparin; calcitonin; erythropoietin; atrial naturetic factor; antigens; monoclonal antibodies; somatostatin; adrenocorticotropin, gonadotropin releasing hormone; oxytocin; vasopressin; cromolyn sodium (sodium or disodium chromoglycate); vancomycin; desferrioxamine (DFO); parathyroid hormone; anti-microbials, including, but not limited to anti-fungal agents; or any combination thereof.

10051-1070